90. 網膜色素変性症 Disease details / Clinical trials / Drug dev / DR info

1.5 X 10^6 UC-MSC + CM
   PT. Prodia Stem Cell Indonesia
      2023   Phase 2/Phase 3   NCT05909488   Indonesia
100 µG brimonidine tartrate implant
   Allergan
      2008   Phase 1/Phase 2   NCT00661479   France;Germany;Portugal;United States
100 µG KIO-301
   Kiora Pharmaceuticals, Inc.
      2025   Phase 2   NCT06628947   -
200 µG brimonidine tartrate implant
   Allergan
      2008   Phase 1/Phase 2   NCT00661479   France;Germany;Portugal;United States
400 µG brimonidine tartrate implant
   Allergan
      2008   Phase 1/Phase 2   NCT00661479   France;Germany;Portugal;United States
4D-125 IVT injection
   4D Molecular Therapeutics
      2020   Phase 1/Phase 2   NCT04517149   United States
50 µG KIO-301
   Kiora Pharmaceuticals, Inc.
      2025   Phase 2   NCT06628947   -
9715X
   Allergan Limited
      2010   -   EUCTR2010-019079-32-PT   Czech Republic;Germany;Italy;Portugal;United Kingdom
      2010   -   EUCTR2010-019079-32-DE   Czech Republic;Germany;Italy;Portugal;United Kingdom
9741X
   Allergan Limited
      2010   -   EUCTR2010-019079-32-PT   Czech Republic;Germany;Italy;Portugal;United Kingdom
      2010   -   EUCTR2010-019079-32-DE   Czech Republic;Germany;Italy;Portugal;United Kingdom
9742X
   Allergan Limited
      2010   -   EUCTR2010-019079-32-PT   Czech Republic;Germany;Italy;Portugal;United Kingdom
      2010   -   EUCTR2010-019079-32-DE   Czech Republic;Germany;Italy;Portugal;United Kingdom
AAV2-REP1
   NightstaRx Ltd
      2018   Phase 3   EUCTR2017-003104-42-GB   Canada;Denmark;Finland;France;Germany;Netherlands;United Kingdom;United States
   NightstaRx Ltd (A Biogen Company)
      2021   Phase 3   EUCTR2017-003104-42-DK   Brazil;Canada;Denmark;Finland;France;Germany;Netherlands;United Kingdom;United States
      2018   Phase 3   EUCTR2017-003104-42-FI   Brazil;Canada;Denmark;Finland;France;Germany;Netherlands;United Kingdom;United States
      2018   Phase 3   EUCTR2017-003104-42-DE   Brazil;Canada;Denmark;Finland;France;Germany;Netherlands;United Kingdom;United States
AAV2/5-HPDE6B
   eyeDNA Therapeutics
      2017   Phase 1/Phase 2   NCT03328130   France
AAV2/5-hrkp.rpgr
   MeiraGTx UK II Limited
      2017   Phase 1;Phase 2   EUCTR2016-003967-21-GB   United Kingdom;United States
   MeiraGTx UK II Ltd
      2018   Phase 1;Phase 2   EUCTR2018-000425-31-GB   United Kingdom;United States
AAV2/5-rpgr
   MeiraGTx UK II Ltd
      2017   Phase 1/Phase 2   NCT03252847   United Kingdom;United States
AAV5-hrkp.rpgr
   JANSSEN CILAG INTERNATIONAL NV
      2022   Phase 3   EUCTR2020-002873-88-IT   Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
   Janssen Pharmaceutical K.K.
      2023   Phase 3   NCT05926583   Japan
   Janssen Research & Development, LLC
      2024   Phase 2   NCT06646289   United States
      2020   Phase 3   NCT04671433   Belgium;Canada;Denmark;France;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
      2017   -   NCT04312672   United Kingdom;United States
   Janssen-Cilag International BV
      2023   Phase 3   EUCTR2020-002873-88-BE   Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
   Janssen-Cilag International NV
      2023   Phase 3   EUCTR2020-002255-37-BE   Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
      2022   Phase 3   EUCTR2020-002873-88-DK   Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
      2022   Phase 3   EUCTR2020-002255-37-NL   Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
      2022   Phase 3   EUCTR2020-002255-37-DK   Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
      -   Phase 1;Phase 2   EUCTR2018-000425-31-Outside-EU/EEA   United Kingdom;United States
   MeiraGTx UK II Limited
      2022   Phase 3   EUCTR2020-002873-88-NL   Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
      2022   Phase 3   EUCTR2020-002873-88-IE   Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
      2022   Phase 3   EUCTR2020-002873-88-FR   Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
      2022   Phase 3   EUCTR2020-002873-88-ES   Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
      2022   Phase 3   EUCTR2020-002255-37-IE   Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
      2022   Phase 3   EUCTR2020-002255-37-ES   Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
      -   Phase 3   EUCTR2020-002873-88-Outside-EU/EEA   Canada;Israel;Switzerland;United Kingdom;United States
      -   Phase 3   EUCTR2020-002873-88-DE   Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
      -   Phase 3   EUCTR2020-002255-37-Outside-EU/EEA   Canada;Israel;Switzerland;United Kingdom;United States
      -   Phase 3   EUCTR2020-002255-37-FR   Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
      -   Phase 3   EUCTR2020-002255-37-DE   Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
AAV5-hrkp.rpgr intermediate dose
   Janssen Research & Development, LLC
      2020   Phase 3   NCT04794101   Belgium;Canada;Denmark;France;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
AAV5-hrkp.rpgr LOW dose
   Janssen Research & Development, LLC
      2020   Phase 3   NCT04794101   Belgium;Canada;Denmark;France;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
AAV8-rpgr
   NightstaRx Limited
      2017   Phase 1;Phase 2;Phase 3   EUCTR2016-003852-60-GB   United Kingdom;United States
   NightstaRx Ltd
      2018   Phase 3   EUCTR2017-003104-42-GB   Canada;Denmark;Finland;France;Germany;Netherlands;United Kingdom;United States
   NightstaRx Ltd (A Biogen Company)
      2021   Phase 3   EUCTR2017-003104-42-DK   Brazil;Canada;Denmark;Finland;France;Germany;Netherlands;United Kingdom;United States
      2018   Phase 3   EUCTR2017-003104-42-FI   Brazil;Canada;Denmark;Finland;France;Germany;Netherlands;United Kingdom;United States
      2018   Phase 3   EUCTR2017-003104-42-DE   Brazil;Canada;Denmark;Finland;France;Germany;Netherlands;United Kingdom;United States
AAVB-081
   AAVantgarde Bio Srl
      2024   Phase 1/Phase 2   NCT06591793   Italy;United Kingdom
ACDN-01
   Ascidian Therapeutics, Inc
      2024   Phase 1/Phase 2   NCT06467344   United States
ACE retino
   Ace Cells Lab Limited
      2024   Phase 1/Phase 2   NCT06787482   Egypt
Acetazolamide
   Kyushu University Hospital
      2016   -   JPRN-UMIN000022686   Japan
Adeno-associated virus type 2 vector encoding RAB escort protein 1
   NightstaRx Ltd (A Biogen Company)
      2021   Phase 3   EUCTR2017-003104-42-DK   Brazil;Canada;Denmark;Finland;France;Germany;Netherlands;United Kingdom;United States
      2018   Phase 3   EUCTR2017-003104-42-FI   Brazil;Canada;Denmark;Finland;France;Germany;Netherlands;United Kingdom;United States
      2018   Phase 3   EUCTR2017-003104-42-DE   Brazil;Canada;Denmark;Finland;France;Germany;Netherlands;United Kingdom;United States
ADX-2191
   Aldeyra Therapeutics, Inc.
      2022   Phase 2   NCT05392179   United States
Aflibercept
   Moorfields Eye Hospital
      2016   Phase 2   EUCTR2015-003723-65-GB   United Kingdom
   Moorfields Eye Hospital NHS Foundation Trust
      2016   Phase 2   NCT02661711   United Kingdom
AGTC-501
   Beacon Therapeutics
      2023   Phase 2   NCT06275620   United States
Alga dunaliella bardawil
   Sheba Medical Center
      2012   Phase 1/Phase 2   NCT01680510   Israel
      2008   -   NCT01256697   Israel
Alga dunaliella bardawil powder
   Sheba Medical Center
      2025   Phase 1/Phase 2   NCT02018692   Israel
Alga dunaliella bardawill
   Sheba Medical Center
      2008   -   NCT01256697   Israel
Allogeneic neural retina-derived human neural retinal progenitor cells EX vivo expanded
   ReNeuron Ltd
      2020   Phase 2   EUCTR2019-004547-77-GB   United Kingdom;United States
Allorx
   The Foundation for Orthopaedics and Regenerative Medicine
      2022   Phase 1   NCT05147701   Antigua and Barbuda;Argentina;Mexico
Amino acids
   Ikeda Hanako
      2019   Phase 2   JPRN-jRCT2051180072   -
Antioxidants
   University of Colorado, Denver
      2008   Phase 2   NCT01773278   United States
Aprokam
   JANSSEN CILAG INTERNATIONAL NV
      2022   Phase 3   EUCTR2020-002255-37-IT   Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
Betametasone DOC
   JANSSEN CILAG INTERNATIONAL NV
      2022   Phase 3   EUCTR2020-002255-37-IT   Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
Betamethasone
   Kyushu University Hospital
      2016   -   JPRN-UMIN000022686   Japan
BIIB111
   NightstaRx Ltd, a Biogen Company
      2018   Phase 3   NCT03584165   Brazil;Canada;Denmark;Finland;France;Germany;Netherlands;United Kingdom;United States
BIIB112
   NightstaRx Ltd, a Biogen Company
      2018   Phase 3   NCT03584165   Brazil;Canada;Denmark;Finland;France;Germany;Netherlands;United Kingdom;United States
      2017   Phase 1/Phase 2   NCT03116113   United Kingdom;United States
Blood and/or skin biopsy
   University Hospital, Lille
      2021   -   NCT04658251   France
Blue light-absorbing sunglasses
   Sun Yat-sen University
      2015   Phase 0   NCT02465749   China
Bmmncs
   Chaitanya Hospital, Pune
      2014   Phase 1/Phase 2   NCT01914913   India
Botaretigene sparoparvovec
   JANSSEN CILAG INTERNATIONAL NV
      2022   Phase 3   EUCTR2020-002873-88-IT   Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
   Janssen-Cilag International BV
      2023   Phase 3   EUCTR2020-002873-88-BE   Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
   Janssen-Cilag International NV
      2023   Phase 3   EUCTR2020-002255-37-BE   Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
      2022   Phase 3   EUCTR2020-002873-88-DK   Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
      2022   Phase 3   EUCTR2020-002255-37-NL   Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
      2022   Phase 3   EUCTR2020-002255-37-DK   Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
      -   Phase 1;Phase 2   EUCTR2018-000425-31-Outside-EU/EEA   United Kingdom;United States
   MeiraGTx UK II Limited
      2022   Phase 3   EUCTR2020-002873-88-NL   Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
      2022   Phase 3   EUCTR2020-002873-88-IE   Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
      2022   Phase 3   EUCTR2020-002873-88-FR   Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
      2022   Phase 3   EUCTR2020-002873-88-ES   Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
      2022   Phase 3   EUCTR2020-002255-37-IE   Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
      2022   Phase 3   EUCTR2020-002255-37-ES   Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
      -   Phase 3   EUCTR2020-002873-88-DE   Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
      -   Phase 3   EUCTR2020-002255-37-FR   Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
      -   Phase 3   EUCTR2020-002255-37-DE   Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
Brimonidine tartrate posterior segment drug delivery system (brimo PS DDS) applicator system
   Allergan Limited
      2010   -   EUCTR2010-019079-32-PT   Czech Republic;Germany;Italy;Portugal;United Kingdom
      2010   -   EUCTR2010-019079-32-DE   Czech Republic;Germany;Italy;Portugal;United Kingdom
BS01
   Bionic Sight LLC
      2020   Phase 1/Phase 2   NCT04278131   United States
Cannabis
   Hadassah Medical Organization
      2018   Early Phase 1   NCT03078309   Israel
CD34+ bone marrow stem cells intravitreal
   University of California, Davis
      2012   Phase 1   NCT01736059   United States
Cefazolina qilu
   JANSSEN CILAG INTERNATIONAL NV
      2022   Phase 3   EUCTR2020-002873-88-IT   Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
      2022   Phase 3   EUCTR2020-002255-37-IT   Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
Cefuroxima
   JANSSEN CILAG INTERNATIONAL NV
      2022   Phase 3   EUCTR2020-002255-37-IT   Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
Cholesterol
   University of Colorado, Denver
      2008   Phase 2   NCT01773278   United States
Ciliary neurotrophic factor implant NT-501
   National Eye Institute (NEI)
      2003   Phase 1   NCT00063765   United States
Circadin 2 MG comprimidos DE liberacióN prolongada
   Isabel Pinilla Lozano
      2012   -   EUCTR2012-002436-82-ES   Spain
Cloramfenicolo fisiopharma - 1 G/10 ML polvere E solvente PER soluzione iniettabile PER USO endovenoso 1 flaconcino polvere + 1 fiala solvente DA 10 ML
   JANSSEN CILAG INTERNATIONAL NV
      2022   Phase 3   EUCTR2020-002255-37-IT   Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
CNS10-NPC implantation
   Cedars-Sinai Medical Center
      2021   Phase 1   NCT04284293   United States
Cnto 2476
   Centocor, Inc.
      2007   Phase 1   NCT00458575   United States
Compound thrombosis capsule SIG: 1.5G/TID
   Sun Yat-sen University
      2015   Phase 0   NCT02465749   China
Continuous oxygen
   Sun Yat-sen University
      2015   Phase 0   NCT02465749   China
Coqun
   POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
      2009   Phase 2   EUCTR2008-004561-26-IT   Italy
Cornstarch control
   National Eye Institute (NEI)
      2003   Phase 3   NCT00346333   United States
Cotoretigene toliparvovec
   NightstaRx Ltd (A Biogen Company)
      2021   Phase 3   EUCTR2017-003104-42-DK   Brazil;Canada;Denmark;Finland;France;Germany;Netherlands;United Kingdom;United States
CPK850
   Novartis Pharma AG
      2018   Phase 1;Phase 2   EUCTR2016-002696-10-SE   Sweden
   Novartis Pharmaceuticals
      2018   Phase 1/Phase 2   NCT03374657   Sweden
Cysteine
   Johns Hopkins University
      2017   Phase 1   NCT03063021   United States
Desametasone
   JANSSEN CILAG INTERNATIONAL NV
      2022   Phase 3   EUCTR2020-002255-37-IT   Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
Dexamethasone
   JANSSEN CILAG INTERNATIONAL NV
      2022   Phase 3   EUCTR2020-002873-88-IT   Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
Dexamethasone injection
   Rafic Hariri University Hospital
      2015   Phase 2   NCT02804360   -
Docosahexaenoic acid
   Retina Foundation of the Southwest
      2004   Phase 2   NCT00100230   United States
      1996   -   NCT00004827   -
Dorzolamide
   Kyushu University Hospital
      2016   -   JPRN-UMIN000022686   Japan
   Kyushu university hospital
      2010   -   JPRN-UMIN000005852   Japan
DSP-3077 retinal sheet cohort 1
   Sumitomo Pharma America, Inc.
      2025   Phase 1/Phase 2   NCT06891885   -
DSP-3077 retinal sheet cohort 2
   Sumitomo Pharma America, Inc.
      2025   Phase 1/Phase 2   NCT06891885   -
DSP-3077 retinal sheet cohort 3
   Sumitomo Pharma America, Inc.
      2025   Phase 1/Phase 2   NCT06891885   -
Dual AAV8.MYO7A
   FONDAZIONE TELETHON
      2023   Phase 1;Phase 2   EUCTR2022-001092-14-IT   Italy;Spain
Ducressa
   JANSSEN CILAG INTERNATIONAL NV
      2022   Phase 3   EUCTR2020-002255-37-IT   Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
EA-2353
   Endogena Therapeutics, Inc
      2022   Phase 1/Phase 2   NCT05392751   United States
Eylea
   Moorfields Eye Hospital
      2016   Phase 2   EUCTR2015-003723-65-GB   United Kingdom
Fluocinolone acetonide
   Moorfields Eye Hospital
      2016   Phase 2   EUCTR2016-002523-28-GB   United Kingdom
FT-002
   Frontera Therapeutics
      2024   Phase 1/Phase 2   NCT06492850   China
      2023   Early Phase 1   NCT05874310   China
Gene therapy product-MCO-010
   Nanoscope Therapeutics Inc.
      2023   -   NCT06162585   Puerto Rico;United States
      2021   Phase 2   NCT04945772   Puerto Rico;United States
Gene therapy product:VMCO-I
   Nanoscope Therapeutics Inc.
      2023   -   NCT05921162   India
      2019   Phase 1/Phase 2   NCT04919473   India
Genetic analysis
   University Hospital, Montpellier
      2009   -   NCT01235624   France
Ginkgo biloba pills SIG: 300MG/TID
   Sun Yat-sen University
      2015   Phase 0   NCT02465749   China
GMP compliant-BM-MSC derived sevs
   Mahidol University
      2024   Phase 1/Phase 2   NCT06242379   Thailand
GS030-DP
   GENSIGHT-BIOLOGICS
      2017   Phase 1;Phase 2   EUCTR2017-002204-27-GB   United Kingdom;United States
HORA-PDE6B
   HORAMA SA
      2017   Phase 1;Phase 2   EUCTR2016-001429-16-FR   France
Hrpc
   ReNeuron Limited
      2015   Phase 1/Phase 2   NCT02464436   Spain;United Kingdom;United States
Hrpc DP
   ReNeuron Ltd
      2020   Phase 2   EUCTR2019-004547-77-GB   United Kingdom;United States
Human primary retinal pigment epithelial (hurpe) cells
   Eyecure Therapeutics Inc.
      2018   Early Phase 1   NCT03566147   China
Human retinal progenitor cells
   jCyte, Inc
      2025   Phase 2   NCT06912633   United States
      2017   Phase 2   NCT03073733   United States
      2015   Phase 1/Phase 2   NCT02320812   United States
Human retinal progenitor cells drug product
   ReNeuron Ltd
      2020   Phase 2   EUCTR2019-004547-77-GB   United Kingdom;United States
Hydroxychloroquine higher dose
   University of Michigan
      2020   Phase 1/Phase 2   NCT04120883   United States
Hydroxychloroquine lower dose
   University of Michigan
      2020   Phase 1/Phase 2   NCT04120883   United States
Hyperbaric oxygen therapy
   Azienda Policlinico Umberto I
      2004   -   NCT00461435   Italy
IGT001
   Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
      2025   Phase 1   NCT06936787   China
Iluvien
   Moorfields Eye Hospital
      2016   Phase 2   EUCTR2016-002523-28-GB   United Kingdom
Injection OF stem cells IN SUB-tenon space OF EYE FOR THE management OF retinitis pigmentosa
   Jinnah Burn and Reconstructive Surgery Centre, Lahore
      2021   Phase 2   NCT04763369   Pakistan
Injection OF stem cells IN suprachoroidal space OF EYE FOR THE management OF retinitis pigmentosa
   Jinnah Burn and Reconstructive Surgery Centre, Lahore
      2021   Phase 2   NCT04763369   Pakistan
Intravitreal autologous CD34+ cells
   University of California, Davis
      2021   Phase 1   NCT04925687   United States
Intravitreal injection OF autologous bone marrow stem cell
   Red de Terapia Celular
      2014   Phase 1   NCT02280135   Spain
Intravitreal injection OF autologous bone marrow stem cells
   University of Sao Paulo
      2011   Phase 2   NCT01560715   Brazil
      2009   Phase 1   NCT01068561   Brazil
Intravitreal injection OF ultevursen
   Laboratoires Thea
      2024   Phase 2   NCT06627179   United Kingdom;United States
Istem-01
   CECS/I-STEM
      2019   Phase 1;Phase 2   EUCTR2018-000457-53-FR   France
Kenacort - 40 MG/ ML sospensione iniettabile 3 flaconcini DA 1 ML
   JANSSEN CILAG INTERNATIONAL NV
      2022   Phase 3   EUCTR2020-002873-88-IT   Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
KIO-301
   Kiora Pharmaceuticals, Inc.
      2022   Phase 1/Phase 2   NCT05282953   Australia
Lentiviral vector containing MYO7A gene
   sanofi-aventis recherche & développement
      2013   Phase 1;Phase 2   EUCTR2012-002574-31-FR   France;United States
Lentiviral vector containing THE human MY07A gene
   sanofi-aventis recherche & développement
      2013   Phase 1;Phase 2   EUCTR2012-002574-31-FR   France;United States
Levodopa-carbidopa
   Beirut Eye Specialist Hospital
      2016   Phase 2   NCT02837640   Lebanon
Lutein
   National Eye Institute (NEI)
      2003   Phase 3   NCT00346333   United States
Lutein (10 or 30 MG/DAY) capsules
   National Center for Complementary and Integrative Health (NCCIH)
      2001   Phase 1/Phase 2   NCT00029289   United States
Lycium barbarum
   The Hong Kong Polytechnic University
      2014   -   NCT02244996   Hong Kong
Melatonin
   Isabel Pinilla Lozano
      2012   -   EUCTR2012-002436-82-ES   Spain
Minocycline
   National Eye Institute (NEI)
      2014   Phase 1/Phase 2   NCT02140164   United States
   Sun Yat-sen University
      2019   Phase 2   NCT04068207   China
Mock injection
   jCyte, Inc
      2025   Phase 2   NCT06912633   United States
      2017   Phase 2   NCT03073733   United States
N-acetylcysteine
   Johns Hopkins University
      2023   Phase 3   NCT05537220   Austria;Canada;Germany;Mexico;Netherlands;Switzerland;United Kingdom;United States
NAC
   Johns Hopkins University
      2017   Phase 1   NCT03063021   United States
NAC effervescent tablets
   Johns Hopkins University
      2019   Phase 1   NCT03999021   United States
Nerve growt factor - 2.5S
   POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
      2009   Phase 2   EUCTR2008-004561-26-IT   Italy
Nerve growth factor
   Ospedale San Raffaele di Milano
      2014   -   EUCTR2014-000385-22-IT   Italy
Nilvadipine
   Department of Ophthalmology, Hirosaki University Graduate School of Medicine
      2001   Phase 2   JPRN-UMIN000007895   Japan
NL-FLVC-001
   University of Colorado, Denver
      2023   Early Phase 1   NCT06565572   United States
NO intervention, will NOT receive ANY active study intervention
   Laboratoires Thea
      2024   Phase 2   NCT06627179   United Kingdom;United States
NPI-001
   Nacuity Pharmaceuticals, Inc.
      2020   Phase 1/Phase 2   NCT04355689   Australia
NT-501
   Neurotech Pharmaceuticals
      2012   Phase 2   NCT01530659   United States
      2007   Phase 2   NCT00447993   United States
      2007   Phase 2   NCT00447980   United States
Nutritional supplement
   National Eye Institute (NEI)
      1996   Phase 3   NCT00000116   United States
Observational
   4D Molecular Therapeutics
      2020   Phase 1/Phase 2   NCT04517149   United States
OCU400
   Ocugen
      2024   -   NCT06574997   United States
OCU400 high dose
   Ocugen
      2022   Phase 1/Phase 2   NCT05203939   United States
OCU400 LOW dose
   Ocugen
      2022   Phase 1/Phase 2   NCT05203939   United States
OCU400 MED dose
   Ocugen
      2022   Phase 1/Phase 2   NCT05203939   United States
Omeprazole
   JANSSEN CILAG INTERNATIONAL NV
      2022   Phase 3   EUCTR2020-002255-37-IT   Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
OPCT-001
   BlueRock Therapeutics
      2025   Phase 1/Phase 2   NCT06789445   United States
Oral disulfiram
   University of Rochester
      2025   Phase 1   NCT06319872   United States
Phosphate
   Kyushu University Hospital
      2016   -   JPRN-UMIN000022686   Japan
Platelet rich plasma
   Ankara Universitesi Teknokent
      2016   -   NCT04238858   Turkey
Prednisone
   FONDAZIONE TELETHON
      2023   Phase 1;Phase 2   EUCTR2022-001092-14-IT   Italy;Spain
Prednisone DOC generici
   JANSSEN CILAG INTERNATIONAL NV
      2022   Phase 3   EUCTR2020-002873-88-IT   Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
Prescribe N-acetylcysteine tablets
   Shahid Beheshti University of Medical Sciences
      2021   Phase 2   NCT04864496   Iran, Islamic Republic of
PRP
   Fondazione Policlinico Universitario Agostino Gemelli IRCCS
      2020   Phase 3   NCT04636853   Italy
PRP combined magnovision
   Ankara Universitesi Teknokent
      2017   -   NCT04252534   -
QLT091001
   QLT Inc.
      2019   Phase 3   EUCTR2013-005393-22-NL   Brazil;Canada;Denmark;France;Germany;Netherlands;Switzerland;United Kingdom;United States
      2016   Phase 3   EUCTR2013-005393-22-DK   Brazil;Canada;Denmark;France;Germany;Netherlands;Switzerland;United Kingdom;United States
      2012   Phase 1   NCT01543906   Canada;Ireland
      2012   Phase 1   NCT01521793   Canada;Germany;Netherlands;United Kingdom;United States
      2012   -   EUCTR2011-004214-42-NL   Canada;Germany;Netherlands;United Kingdom;United States
      2012   Phase 1   EUCTR2011-004214-42-GB   Canada;Germany;Netherlands;United Kingdom;United States
      2012   -   EUCTR2011-004214-42-DE   Canada;Germany;Netherlands;United Kingdom;United States
      2009   Phase 1   NCT01014052   Canada;Germany;Netherlands;United Kingdom;United States
QR-1123
   ProQR Therapeutics
      2019   Phase 1/Phase 2   NCT04123626   United States
QR-421A
   ProQR Therapeutics
      2021   Phase 2/Phase 3   NCT05176717   United Kingdom;United States
      2019   Phase 1/Phase 2   NCT03780257   Belgium;Canada;France;United States
      2019   Phase 1;Phase 2   EUCTR2018-002433-38-FR   Belgium;Canada;France;United States
   ProQR Therapeutics IV B.V.
      -   Phase 2;Phase 3   EUCTR2021-002729-74-NO   Brazil;Canada;European Union;Germany;Norway;United Kingdom;United States
      -   Phase 2;Phase 3   EUCTR2021-002729-74-NL   Brazil;Canada;European Union;Germany;Netherlands;Norway;United Kingdom;United States
      -   Phase 2;Phase 3   EUCTR2021-002729-74-DK   Brazil;Canada;Denmark;European Union;Germany;Netherlands;Norway;United Kingdom;United States
      -   Phase 2;Phase 3   EUCTR2021-002728-19-NO   Brazil;Canada;Denmark;European Union;France;Germany;Netherlands;Norway;United Kingdom;United States
      -   Phase 2;Phase 3   EUCTR2021-002728-19-NL   Brazil;Canada;European Union;Germany;Netherlands;Norway;United Kingdom;United States
      -   Phase 2;Phase 3   EUCTR2021-002728-19-FR   Brazil;Canada;European Union;France;Germany;Netherlands;Norway;United Kingdom;United States
      -   Phase 2;Phase 3   EUCTR2021-002728-19-DK   Brazil;Canada;Denmark;European Union;France;Germany;Netherlands;Norway;United Kingdom;United States
Raav.HPDE6A vector
   Universitätsklinikum Tübingen
      2019   Phase 1;Phase 2   EUCTR2016-003705-34-DE   Germany
RAAV2TYF-GRK1-hrpgrco
   Beacon Therapeutics
      2024   Phase 2/Phase 3   NCT04850118   Australia;Israel;Netherlands;United Kingdom;United States
RAAV2TYF-GRK1-rpgr
   Beacon Therapeutics
      2021   Phase 2   NCT06333249   United States
      2018   Phase 1/Phase 2   NCT03316560   United States
Recombinant adeno-associated viral vector serotype 2.7m8 containing THE chrimsonr-tdtomato gene
   GENSIGHT-BIOLOGICS
      2017   Phase 1;Phase 2   EUCTR2017-002204-27-GB   United Kingdom;United States
Retinal pigment epitheliums transplantation
   Qi Zhou
      2020   Phase 1   NCT03944239   China
Rhngf 180 µG/ML EYE drops solution
   Dompé Farmaceutici S.p.A
      2014   Phase 1/Phase 2   NCT02110225   Italy
   Ospedale San Raffaele
      2015   Phase 2   NCT02609165   Italy
Rhngf 60 µG/ML EYE drops solution
   Dompé Farmaceutici S.p.A
      2014   Phase 1/Phase 2   NCT02110225   Italy
RNA antisense oligonucleotide FOR intravitreal injection
   ProQR Therapeutics
      2021   Phase 2   NCT05085964   Canada;France;United States
RST-001
   AbbVie
      2015   Phase 1/Phase 2   NCT02556736   United States
RTX-015
   Ray Therapeutics, Inc.
      2024   Phase 1   NCT06460844   United States
SAR421869
   Sanofi
      2012   Phase 1/Phase 2   NCT01505062   France;United States
   sanofi-aventis recherche & développement
      2013   Phase 1;Phase 2   EUCTR2012-002574-31-FR   France;United States
Sham
   Allergan
      2008   Phase 1/Phase 2   NCT00661479   France;Germany;Portugal;United States
   Neurotech Pharmaceuticals
      2012   Phase 2   NCT01530659   United States
Sham injection
   Nanoscope Therapeutics Inc.
      2021   Phase 2   NCT04945772   Puerto Rico;United States
Sham procedure
   ProQR Therapeutics
      2019   Phase 1/Phase 2   NCT04123626   United States
SHAM-procedure
   Laboratoires Thea
      2021   Phase 2/Phase 3   NCT05158296   Germany;Netherlands;United Kingdom;United States
   ProQR Therapeutics
      2021   Phase 2/Phase 3   NCT05176717   United Kingdom;United States
      2019   Phase 1/Phase 2   NCT03780257   Belgium;Canada;France;United States
SPVN06
   SparingVision
      2023   Phase 1/Phase 2   NCT05748873   France;United States
Standard OF care sildenafil
   Columbia University
      2014   Phase 2   NCT04356716   United States
Stem cell implantation
   Acibadem University
      2019   Phase 1/Phase 2   NCT05712148   Turkey
Stem cell transplantation
   Stem Cells Arabia
      2014   Phase 1/Phase 2   NCT02709876   Jordan
Stem/progenitor cells transplantation
   Pomeranian Medical University Szczecin
      2018   Phase 1   NCT03772938   Poland
SUB-retinal administration OF OCU400-301
   Ocugen
      2024   Phase 3   NCT06388200   Canada;United States
Subconjunctival injection OF saline
   Red de Terapia Celular
      2014   Phase 1   NCT02280135   Spain
Subretinal administration OF RAAV2-VMD2-hmertkrecombinant adeno-associated virus
   King Khaled Eye Specialist Hospital
      2011   Phase 1   NCT01482195   Saudi Arabia
Subretinal injection OF raav.HPDE6A
   STZ eyetrial
      2019   Phase 1/Phase 2   NCT04611503   Germany
Subtenon injection OF wharton jelly derived mesenchymal stem cell exosomes
   TC Erciyes University
      2022   Phase 2/Phase 3   NCT05413148   Turkey
Subtenon injection OF wharton jelly derived mesenchymal stem cells
   TC Erciyes University
      2022   Phase 2/Phase 3   NCT05413148   Turkey
Sugar pill
   Sheba Medical Center
      2008   -   NCT01256697   Israel
TBD
   Novartis Pharma AG
      2018   Phase 1;Phase 2   EUCTR2016-002696-10-SE   Sweden
Timrepigene emparvovec
   NightstaRx Ltd
      2018   Phase 3   EUCTR2017-003104-42-GB   Canada;Denmark;Finland;France;Germany;Netherlands;United Kingdom;United States
   NightstaRx Ltd (A Biogen Company)
      2021   Phase 3   EUCTR2017-003104-42-DK   Brazil;Canada;Denmark;Finland;France;Germany;Netherlands;United Kingdom;United States
      2018   Phase 3   EUCTR2017-003104-42-FI   Brazil;Canada;Denmark;Finland;France;Germany;Netherlands;United Kingdom;United States
      2018   Phase 3   EUCTR2017-003104-42-DE   Brazil;Canada;Denmark;Finland;France;Germany;Netherlands;United Kingdom;United States
Tobramicina E desametasone DOC generici
   JANSSEN CILAG INTERNATIONAL NV
      2022   Phase 3   EUCTR2020-002873-88-IT   Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
Tocoferol
   Department of Ophthalmology, Hirosaki University Graduate School of Medicine
      2001   Phase 2   JPRN-UMIN000007895   Japan
Triamcinolone
   JANSSEN CILAG INTERNATIONAL NV
      2022   Phase 3   EUCTR2020-002873-88-IT   Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
   Kyushu University Hospital
      2016   -   JPRN-UMIN000022686   Japan
Twice-daily dosage with 0.5% cyclosporine-A eyedrops
   Semmelweis University
      2007   -   NCT00433277   Hungary
UF-021
   R-Tech Ueno, Ltd
      2013   Phase 3   JPRN-jRCT2080222033   -
      2009   Phase 2   JPRN-jRCT2080220721   -
   R-Tech Ueno, Ltd.
      2013   Phase 3   NCT01786395   Japan
Ultevursen
   Laboratoires Thea
      2021   Phase 2/Phase 3   NCT05158296   Germany;Netherlands;United Kingdom;United States
Unoprostone
   Kyushu university hospital
      2009   -   JPRN-UMIN000006820   Japan
   R-Tech Ueno, Ltd
      2013   Phase 3   JPRN-jRCT2080222033   -
      2009   Phase 2   JPRN-jRCT2080220721   -
Ushstat
   sanofi-aventis recherche & développement
      2013   Phase 1;Phase 2   EUCTR2012-002574-31-FR   France;United States
Valproate
   Yasuhiko Hirami
      2010   -   JPRN-jRCT1091220053   Japan
Valproic acid
   Foundation Fighting Blindness Clinical Research Institute
      2010   Phase 2   NCT01233609   United States
   Seoul National University Hospital
      2011   Phase 2   NCT01399515   Korea, Republic of
Vehicle EYE drops
   Ospedale San Raffaele
      2015   Phase 2   NCT02609165   Italy
VG901
   ViGeneron GmbH
      2023   Phase 1   NCT06291935   Germany
Vitamin A
   National Eye Institute (NEI)
      2003   Phase 1   NCT00065455   United States
      1996   Phase 3   NCT00000116   United States
      1984   Phase 3   NCT00000114   -
Vitamin AD SIG: 1 tablet/TID
   Sun Yat-sen University
      2015   Phase 0   NCT02465749   China
Vitamin B SIG: 10MG/TID
   Sun Yat-sen University
      2015   Phase 0   NCT02465749   China
Vitamin E
   National Eye Institute (NEI)
      1984   Phase 3   NCT00000114   -
VP-001
   PYC Therapeutics
      2025   Phase 1/Phase 2   NCT06852963   United States
      2024   Phase 1   NCT06455826   United States
Wharton'S jelly derived mesenchymal stem cell
   Ankara Universitesi Teknokent
      2019   Phase 3   NCT04224207   Turkey
ZM-02-H
   Zhongmou Therapeutics
      2024   Early Phase 1   NCT06292650   China
ZM-02-L
   Zhongmou Therapeutics
      2024   Early Phase 1   NCT06292650   China
ZM-02-S
   Zhongmou Therapeutics
      2024   Early Phase 1   NCT06292650   China
Zuretinol acetate
   QLT Inc.
      2019   Phase 3   EUCTR2013-005393-22-NL   Brazil;Canada;Denmark;France;Germany;Netherlands;Switzerland;United Kingdom;United States
      2016   Phase 3   EUCTR2013-005393-22-DK   Brazil;Canada;Denmark;France;Germany;Netherlands;Switzerland;United Kingdom;United States
ZVS203E
   Chigenovo Co., Ltd
      2025   Phase 1/Phase 2   NCT06952842   China
   Peking University Third Hospital
      2023   Early Phase 1   NCT05805007   China